Last updated: 14 March 2023 at 4:48pm EST

Andrew Balo Net Worth

The estimated Net Worth of Andrew K Balo is at least $41.3 million dollars as of 9 September 2021. Mr. Balo owns over 5,597 units of Dexcom Inc stock worth over $517,154 and over the last 19 years he sold DXCM stock worth over $37,753,374. In addition, he makes $3,022,690 as Executive Vice President - Regulatory Strategy, Clinical Affairs et and Strategic Partnership Development at Dexcom Inc.

Mr. Balo DXCM stock SEC Form 4 insiders trading

Andrew has made over 101 trades of the Dexcom Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 5,597 units of DXCM stock worth $3,060,328 on 9 September 2021.

The largest trade he's ever made was exercising 55,000 units of Dexcom Inc stock on 20 June 2016 worth over $175,450. On average, Andrew trades about 6,682 units every 26 days since 2005. As of 9 September 2021 he still owns at least 7,553 units of Dexcom Inc stock.

You can see the complete history of Mr. Balo stock trades at the bottom of the page.

Andrew Balo biography

Andrew K. Balo serves as Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development of the Company. He has served as our Executive Vice President of Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development since May 2016. From January 2015 until April 2016 Mr. Balo served as our Executive Vice President, Clinical, Regulatory and Quality. From March 2008 to January 2015, Mr. Balo served as our Senior Vice President of Clinical and Regulatory Affairs, and from February 2002 to March 2008, served as our Vice President of Clinical and Regulatory Affairs. From June 1999 to February 2002, Mr. Balo served as Vice President, Regulatory and Clinical Affairs of Innercool Therapies, Inc., a medical technology company. Mr. Balo has held several positions at St. Jude Medical including Clinical, Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company. Mr. Balo received a B.S. from the University of Maryland.

What is the salary of Andrew Balo?

As the Executive Vice President - Regulatory Strategy, Clinical Affairs et and Strategic Partnership Development of Dexcom Inc, the total compensation of Andrew Balo at Dexcom Inc is $3,022,690. There are 3 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.

How old is Andrew Balo?

Andrew Balo is 72, he's been the Executive Vice President - Regulatory Strategy, Clinical Affairs et and Strategic Partnership Development of Dexcom Inc since 2016. There are 2 older and 27 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..

What's Andrew Balo's mailing address?

Andrew's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.

Insiders trading at Dexcom Inc

Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff et Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.

What does Dexcom Inc do?

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.

Complete history of Mr. Balo stock trades at Dexcom Inc

Initié	Trans. Transaction	Prix total
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$3,060,328 9 Sep 2021
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$1,422,254 3 Aug 2021
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$1,279,236 6 Jul 2021
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$896,625 3 Jun 2021
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$2,020,013 10 Mar 2021
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$2,088,472 15 Sep 2020
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$1,824,214 9 Sep 2020
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$2,390,117 15 Jun 2020
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$1,895,879 15 Apr 2020
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$2,161,196 11 Mar 2020
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$361,384 18 Sep 2019
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$1,380,257 9 Sep 2019
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$6,290 3 Sep 2019
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$978,125 5 Jun 2019
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$1,558,838 12 Mar 2019
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$606,150 14 Dec 2018
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$715,650 14 Nov 2018
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$623,950 12 Oct 2018
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$725,850 14 Sep 2018
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$803,187 10 Sep 2018
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$621,250 14 Aug 2018
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$497,800 16 Jul 2018
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$198,691 11 Dec 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$389,400 29 Nov 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$234,444 11 Sep 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$230,908 10 Aug 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$228,960 10 Jul 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$220,992 12 Jun 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$230,176 10 May 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$250,208 10 Apr 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$248,672 10 Mar 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$253,760 10 Feb 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$253,760 10 Feb 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$31,360 10 Jan 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$31,360 10 Jan 2017
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$411,303 19 Oct 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$412,750 5 Oct 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$464,350 21 Sep 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$15,947 7 Sep 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$15,950 24 Aug 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$15,950 10 Aug 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$15,950 27 Jul 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$15,950 13 Jul 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$15,950 29 Jun 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$175,450 20 Jun 2016
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$23,925 17 Dec 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$23,925 3 Dec 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$23,925 25 Nov 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$31,900 23 Nov 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$23,925 11 Nov 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$369,665 20 Oct 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$676,095 6 Oct 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$791,558 21 Sep 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$671,475 8 Sep 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$693,525 20 Aug 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$712,800 6 Aug 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$865,943 22 Jul 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$360,509 8 Jul 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$54,615 23 Jun 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 9 Jun 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 18 May 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 4 May 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 23 Apr 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 9 Apr 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 25 Mar 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 11 Mar 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 24 Feb 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$73,500 10 Feb 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$125,258 26 Jan 2015
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 26 Dec 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 11 Dec 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 25 Nov 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 11 Nov 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 27 Oct 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 13 Oct 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 25 Sep 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 10 Sep 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$76,300 25 Aug 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$63,800 22 Aug 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$89,400 11 Aug 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$89,400 25 Jul 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$89,400 11 Jul 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$89,400 25 Jun 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$89,400 11 Jun 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$72,500 27 May 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$72,500 12 May 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$72,500 25 Apr 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$72,500 11 Apr 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$72,500 25 Mar 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$72,500 11 Mar 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$72,500 25 Feb 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$107,800 11 Feb 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$143,000 27 Jan 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$143,000 13 Jan 2014
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$488,108 3 Dec 2013
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$101,333 11 Nov 2013
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$24,000 13 Jun 2013
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$108,000 13 May 2013
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$7,708 11 Mar 2013
Andrew K Balo EVP Regulatory Strategy Clinic	Vente	$178,257 13 Dec 2012
Andrew K Balo EVP Regulatory Strategy Clinic	Exercice d'option	$14,233 18 May 2012

Dexcom Inc executives and stock owners

Dexcom Inc executives and other stock owners filed with the SEC include:

Kevin Sayer,
Chairman of the Board, President, Chief Executive Officer
Quentin Blackford,
Chief Financial Officer, Chief Operating Officer
Richard Doubleday,
Executive Vice President, Chief Commercial Officer
Andrew Balo,
Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development
Steven Pacelli,
Executive Vice President - Strategy and Corporate Development
Donald Abbey,
Executive Vice President - Quality and Regulatory Affairs
Kevin Ronald Sayer,
Exec. Chairman, CEO & Pres
Jacob Steven Leach,
Exec. VP & CTO
Bridgette Heller,
Independent Director
Mark Foletta,
Lead Independent Director
Eric Topol,
Independent Director
Jay Skyler,
Independent Director
Nicholas Augustinos,
Independent Director
Steven Altman,
Independent Director
Barbara Kahn,
Independent Director
Richard Collins,
Independent Director
Kyle Malady,
Independent Director
Karen Dahut,
Independent Director
Shelly Selvaraj,
Senior Vice President - Information Technology
Jeffrey Moy,
Senior Vice President - Operations
Jereme Sylvain,
Senior Vice President - Finance, Chief Accounting Officer
Patrick Murphy,
Executive Vice President, Chief Legal Officer
Jake Leach,
Executive Vice President, Chief Technology Officer
Shelly Ramasamy Selvaraj,
Sr. VP of Information Technology
Donald M. Abbey,
Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs
Steven R. Pacelli,
Exec. VP & MD of Dexcom Ventures
Andrew K. Balo,
Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel.
Sadie M. Stern,
Exec. VP & Chief HR Officer
Chad M. Patterson,
Exec. VP of Global Marketing
Sean Christensen,
Director of Corp. Affairs & Head of Investor Relations
Jereme M. Sylvain,
Exec. VP, CFO & Chief Accounting Officer
John Lister,
VP, Legal Affairs
Terrance H Gregg,
Director
Jess Roper,
VP, CFO
Jorge A Valdes,
Vice President of Engineering
Girish Naganathan,
EVP Chief Technology Officer
Heather S Ace,
SVP Human Resources
Kevin M Sun,
VP, Corp Controller & Treasury
Jonathan T Md Lord,
Director
Glen D Nelson,
Director
Peter Gerhardsson,
VP, Int'l Business Development
David Carner,
VP, Quality Assurance
Laura Johnson,
V.P., Intellectual Property
Martin Doordan,
Director
Sean Carney,
Director
John Riolo,
VP of Quality Assurance
Claudia Graham,
VP, Marketing
Donald A Lucas,
Director
Donald L Lucas,
Director
Mark Brister,
VP, Advanced Development Teams
Richard Yang,
V.P., Strategic Affairs
James H Brauker,
VP, Research & Development
Rodney L Kellogg,
Vice President of Sales
Andrew P Rasdal,
President and CEO
Steven J Kemper,
Chief Financial Officer
Kim D Blickenstaff,
Director
Tae Andrews,
Vice President of Marketing
Paul Travelers Companies In...,
Pincus Private Equity Viii ...,
Brenton Karl Ahrens,
Director
Nancy Sfog City Management ...,
Equity Partners Ii Llccanaa...,
Paul Travelers Companies In...,
Eric A Charmers Landing Llc...,
Scott Lwindamere Llcwindame...,
Equity Partners Ii Llc Waub...,
Teri L Lawver,
EVP Chief Commercial Officer
Paul R Flynn,
EVP Global Revenue
Matthew Vincent Dolan,
EVP Strategy and Corporate Dev
Sumi Shrishrimal,
SVP Chief Risk Officer
Chad Patterson,
EVP Global Marketing
Barry J. Regan,
EVP Operations
Jacob Steven Leach,
EVP, Chief Operating Officer
Rimma Driscoll,
Director
Michael Jon Brown,
EVP, Chief Legal Officer
Sadie Stern,
EVP, Chief HR Officer